The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI